Format

Send to

Choose Destination
See comment in PubMed Commons below
Respir Res. 2010 Jun 16;11:78. doi: 10.1186/1465-9921-11-78.

Interleukin-17 regulation: an attractive therapeutic approach for asthma.

Author information

1
Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, South Korea.

Abstract

Interleukin (IL)-17 is recognized to play a critical role in numerous immune and inflammatory responses by regulating the expression of various inflammatory mediators, which include cytokines, chemokines, and adhesion molecules. There is growing evidence that IL-17 is involved in the pathogenesis of asthma. IL-17 orchestrates the neutrophilic influx into the airways and also enhances T-helper 2 (Th2) cell-mediated eosinophilic airway inflammation in asthma. Recent studies have demonstrated that not only inhibitor of IL-17 per se but also diverse regulators of IL-17 expression reduce antigen-induced airway inflammation, bronchial hyperresponsiveness, and Th2 cytokine levels in animal models of asthma. This review will summarize the role of IL-17 in the context of allergic airway inflammation and discuss the therapeutic potential of various strategies targeting IL-17 for asthma.

PMID:
20565710
PMCID:
PMC2894770
DOI:
10.1186/1465-9921-11-78
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center